EyePoint (EYPT) Pharmaceuticals announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYU, formerly EYP-1901, for the treatment of wet age-related macular degeneration. DURAVYU is an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor formulated in proprietary bioerodible Durasert E.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT: